Active Insight: Rodenticides in This Series, the Chemisty of Major Pesticide Groups Are Examined Steve Broadbent

Total Page:16

File Type:pdf, Size:1020Kb

Active Insight: Rodenticides in This Series, the Chemisty of Major Pesticide Groups Are Examined Steve Broadbent F E A T U R E Active Insight: Rodenticides In this series, the chemisty of major pesticide groups are examined Steve Broadbent he development of the modern medicinal ‘thinning’ of blood. A few years later, anticoagulant rodenticides is a in 1945, while recovering from a recurrence Tfascinating story, and quite different of tuberculosis, Dr Link was reading about the to what one might expect. For centuries history of rat control. Rodents were a serious ‘physicians’ had proposed that ‘thinning’ the problem for the farmers he had worked with in blood was an effective treatment for various the isolation of dicoumarol, and he wanted to maladies. In earlier centuries the prescription of see if he could help them out. He considered leeches was common for this purpose. dicoumarol but thought it better to avoid its use as a rodenticide, as he felt it would detract from With this in mind, the story of the development its human therapeutic uses. He therefore looked of modern oral anticoagulants starts with at the range of products his lab had developed haemorrhagic disease in cattle in the Midwest from the coumarin work overall. of the USA in the 1920s. This disease was These efforts to develop an effective rodenticide characterised by severe internal bleeding. resulted in his team’s synthesis of warfarin The cause was eventually traced back to the (derived from Wisconsin Alumni Research ingestion of spoiled sweet clover. Scientists Foundation). Warfarin was first introduced as worked to determine what the substance a rodenticide in 1952 and, oddly enough, two was that was causing the bleeding. This years later it was approved for human medical was eventually extracted and identified as a use, despite this having been Dr Link’s concern coumarin compound. This work, by Dr Karl Paul with dicoumarol! Link and his team, working at the University of Wisconsin, went on to prove that it was actually Coumarins, as these compounds are known, a fungal metabolite that had developed in the block the chemical reduction of vitamin K, spoiled sweet clover which had caused the which is an essential component in the clotting internal bleeding. of blood. The ‘K’ in vitamin K comes from the German word koagulation. Today warfarin is This led to the development and probably most well known as a therapeutic commercialisation of dicoumarol in 1941 for the agent given to humans to prevent thrombosis, 44 || FAOPMA Newsletter - April 2020 F Acute LD50* Active Rattus norvegicus E Warfarin 10.0 – 20.0 mg/Kg A Fumarin 125.0 mg/Kg T U Diphacinone 2.3 – 43.0 mg/Kg R Chlorphacinone 20.5 mg/Kg E Pindone 10.0 mg/Kg Coumatetralyl 16.0 mg/Kg Difenacoum 1.8 mg/Kg Brodifacoum 0.22 – 0.27 mg/Kg Bromadiolone 1.1 – 1.8 mg/Kg Flocoumafen 0.25 – 0.56 mg/Kg Difethialone 0.56 mg/Kg *Source: Rodent Pests and their Control. Dr. AP Buckle & Prof. RH Smith ISBN: 0 85198 8202 the formation of potentially life-threatening very poor as a mouse killer. clots in veins or arteries. In the 1960s the rodenticidal value of pindone Warfarin has a strong taste deterrent that has was recognised. Pindone had originally been to be disguised to ensure the rodents are not developed as an insecticide by Motomco Ltd. deterred from feeding, and will eat poisoned As an anticoagulant rodenticide it also exhibits feed for several days; or at least until the insecticidal and mould inhibiting qualities, symptoms of poisoning set in. Rodent death even in its commercial form at 0.025%. All these from warfarin typically takes up to six days. It products are multi-feed, so the rodent has to causes a slow death through the gradual onset feed over several days to incur a lethal dose. of internal bleeding. Further first-generation rodenticides entered the market during the Within a decade of warfarin’s introduction, 1950s and 60s, and still remain in use. In the rats and mice resistant to the poison were 1950s came fumarin from Amchem, a subsidiary discovered. The demise of warfarin in rodent of Union Carbide. Then came a more potent control programs though is more attributable to group of products starting with diphacinone, the development of the more effective, second- patented by Upjohn Corporation; coumatetralyl generation anticoagulant rodenticides. from Bayer was developed in 1956; and in 1961 Ward Benkinsop in the United Kingdom, the chlorphacinone came from Liphatech. These company that became Sorex (now part of BASF), latter products offer greater toxicity to rodents, developed the first of these second-generation but also to non-target species. Diphacinone is WWW.FAOPMA.COM || 45 F products, difenacoum, which was quickly Whilst death may occur from a single ingestion, followed by brodifacoum. At about the same it usually takes 3 – 4 days for the rodents to E time, Liphatech developed bromadiolone, and actually die, which minimises the onset of A later difethialone. As a small UK based company, bait shyness. Mice are generally much harder Ward Benkinsop licensed brodifacoum and to kill with anticoagulants, which has given T difenacoum to ICI for worldwide development. brodifacoum an edge as it is the best mouse Later, when Shell bought out Sorex, the team killing compound. U from Ward Benkinsop were asked to develop a R further compound. This led to the development The major control technology for rodents is of flocoumafen. These are all coumarin derived the use of baits formulated from proprietary E compounds. They remain highly effective, mixtures of cereals and wax-based substances. though genetic mutations conferring resistance An important aspect of bait development is the to them has been identified in both atsr and presence of both olfactory compounds that mice. will draw the rodents to the bait; and then the presence of high-quality cereal and protein feed Second-generation actives are used at much to ensure rodent feeding. The wax component lower dose rates, but have raised concerns is a trade-off in block baits. Higher wax content over secondary poisoning, especially of raptors baits will keep their form better in high (birds of prey), which feed on the rodents killed temperature environments, but this is ‘traded- by these poisons. This has led again to the use off’ against their reduced palatability. This has of first-generation products in some sensitive led to the development of extruded block baits, areas; though recent studies indicate these too which are compressed and therefore use less are of concern with respect to the poisoning of wax. More recently, soft baits, often referred birds, especially diphacinone. to as pasta baits and gel baits, which have the highest palatability have entered the market. It is the single-feed aspects of the second- The single-feed action of the second-generation generation anticoagulants that has conferred baits is dependent upon a highly attractive the greatest benefits. Technically, only feed component, which usually means a more brodifacoum and flocoumafen are true ‘single- expensive product to ensure consumption. feed’ products, as their potency allows for the control of all rodents under all conditions, Steve Broadbent is the Regional Director, through a single-feed. The reality though is Australia, SE Asia, South Africa & Gulf Region, that all the second-generation products are Ensystex, Australia. single feed in most conditions on most species. Email: [email protected] 46 || FAOPMA Newsletter - April 2020 .
Recommended publications
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Wastewater-Borne Exposure of Limnic Fish to Anticoagulant Rodenticides
    Water Research 167 (2019) 115090 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres Wastewater-borne exposure of limnic fish to anticoagulant rodenticides * Julia Regnery a, , Pia Parrhysius a, Robert S. Schulz a, Christel Mohlenkamp€ a, Georgia Buchmeier b, Georg Reifferscheid a, Marvin Brinke a a Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, Am Mainzer Tor 1, 56068 Koblenz, Germany b Unit Aquatic Ecotoxicology, Microbial Ecology, Bavarian Environment Agency, Demollstr. 31, 82407 Wielenbach, Germany article info abstract Article history: The recent emergence of second-generation anticoagulant rodenticides (AR) in the aquatic environment Received 18 June 2019 emphasizes the relevance and impact of aquatic exposure pathways during rodent control. Pest control Received in revised form in municipal sewer systems of urban and suburban areas is thought to be an important emission 12 September 2019 pathway for AR to reach wastewater and municipal wastewater treatment plants (WWTP), respectively. Accepted 13 September 2019 To circumstantiate that AR will enter streams via effluent discharges and bioaccumulate in aquatic or- Available online 14 September 2019 ganisms despite very low predicted environmental emissions, we conducted a retrospective biological monitoring of fish tissue samples from different WWTP fish monitoring ponds exclusively fed by Keywords: fl Bioaccumulation municipal ef uents in Bavaria, Germany. At the same time, information about rodent control in asso- Biocides ciated sewer systems was collected by telephone survey to assess relationships between sewer baiting Monitoring and rodenticide residues in fish. In addition, mussel and fish tissue samples from several Bavarian surface PBT-Substances waters with different effluent impact were analyzed to evaluate the prevalence of anticoagulants in Sewer baiting indigenous aquatic organisms.
    [Show full text]
  • Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound.
    [Show full text]
  • Some Rodenticidal Properties of Coumatetralyl
    J.Hyg.,Camb. (1969), 67, 311 311 Printed in Great Britain Some rodenticidal properties of coumatetralyl BY J. H. GREAVES AND PRISCILLA AYRES Infestation Control Laboratory, Ministry of Agriculture, Fisheries and Food, Tolworth, Surrey {Received 26 September 1968) INTRODUCTION Coumatetralyl (3-(a-tetralyl)-4-hydroxycoumarin), an anti-coagulant rodenti- cide developed by Farbenfabriken Bayer A.G., has been used extensively against rats in Germany (Schultze, 1965). Comparatively little information is available, however, concerning its rodenticidal properties. The present laboratory study was therefore undertaken to investigate the toxicity of the anti-coagulant to warfarin- resistant and warfarin-susceptible rats (Rattus norvegicus Berk.) and to compare its palatability with that of warfarin (3-(<x-acetonylbenzyl)-4-hydroxycoumarin). METHODS Wild rats, presumed not to be resistant to warfarin (NR rats) were caught in a Midlands refuse destructor and on a Surrey farm. Warfarin-resistant (WR) rats were trapped on farms in three different areas of Britain: Nottinghamshire (WR Notts), Gloucestershire (WR Glos) and the Salop-Montgomeryshire area (WR Welsh). Field investigations had shown that the rats on the Nottinghamshire and Gloucestershire farms could not be controlled with warfarin. All ten WR Glos rats used in tests with coumatetralyl had first been given, and had survived, un- restricted feeding for 6 days on 0-005 % warfarin in the laboratory and similarly all but six of the 23 WR Notts rats had first been given periods of from 3 to 6 days on warfarin. The 53 WR Welsh animals had survived either 6 days feeding on 0-005 % warfarin or a single subcutaneous injection of 200 mg./kg.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals.
    [Show full text]
  • Heavy Rainfall Provokes Anticoagulant Rodenticides' Release from Baited
    Journal Pre-proof Heavy rainfall provokes anticoagulant rodenticides’ release from baited sewer systems and outdoor surfaces into receiving streams Julia Regnery1,*, Robert S. Schulz1, Pia Parrhysius1, Julia Bachtin1, Marvin Brinke1, Sabine Schäfer1, Georg Reifferscheid1, Anton Friesen2 1 Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, 56068 Koblenz, Germany 2 Section IV 1.2 Biocides, German Environment Agency, 06813 Dessau-Rosslau, Germany *Corresponding author. Email: [email protected] (J. Regnery); phone: +49 261 1306 5987 Journal Pre-proof A manuscript prepared for possible publication in: Science of the Total Environment May 2020 1 Journal Pre-proof Abstract Prevalent findings of anticoagulant rodenticide (AR) residues in liver tissue of freshwater fish recently emphasized the existence of aquatic exposure pathways. Thus, a comprehensive wastewater treatment plant and surface water monitoring campaign was conducted at two urban catchments in Germany in 2018 and 2019 to investigate potential emission sources of ARs into the aquatic environment. Over several months, the occurrence and fate of all eight ARs authorized in the European Union as well as two pharmaceutical anticoagulants was monitored in a variety of aqueous, solid, and biological environmental matrices during and after widespread sewer baiting with AR-containing bait. As a result, sewer baiting in combined sewer systems, besides outdoor rodent control at the surface, was identified as a substantial contributor of these biocidal active ingredients in the aquatic environment. In conjunction with heavy or prolonged precipitation during bait application in combined sewer systems, a direct link between sewer baiting and AR residues in wastewater treatment plant influent, effluent, and the liver of freshwater fish was established.
    [Show full text]
  • Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
    SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s)
    [Show full text]
  • Drug Interactions and Lethal Drug Combinations
    J Clin Pathol: first published as 10.1136/jcp.28.Suppl_9.94 on 1 January 1975. Downloaded from J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 94-98 The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations ALAN RICHENS From the Department of Clinical Pharmacology, St Bartholomew's Hospital, London Although the development of drugs of greater example, aspirin can displace oral anticoagulants potency and efficacy confers on the physician from their plasma-protein-binding sites, and in- increasing power to treat serious diseases, it also directly acting sympathomimetics contained in cough increases the number and seriousness of potential mixtures can cause a hypertensive crisis in patients adverse effects and drug interactions which can on monoamine oxidase inhibitors. Self-medication is occur. Most hospital patients receive more than one common, and often involves drugs obtained on drug at a time, the average number often being prescription for a previous illness. greater than five (Smith, Seidl, and Cluff, 1966). The 4 When several clinics or doctors are involved in incidence of drug reactions rises with the number of the care of a patient, one doctor may not be aware of drugs prescribed simultaneously. In patients pre- what another has prescribed. scribed one to five drugs the incidence of reactions is 5 When preparations which contain more than 18-6%, while in patients prescribed six or more one ingredient are prescribed by their trade names. it rises to 814 % (Hurwitz and Wade, 1969). There are a number of ways in which drugs may The Boston Collaborative Drug Surveillance interact.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Dicoumarol: a Unique Microtubule Stabilizing Natural Product That Is Synergistic with Taxol1
    [CANCER RESEARCH 63, 1214–1220, March 15, 2003] Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol1 Hamta Madari, Dulal Panda, Leslie Wilson, and Robert S. Jacobs2 Departments of Ecology, Evolution, and Marine Biology [H. M., R. S. J.] and Molecular, Cellular, and Developmental Biology [L. W.], University of California, Santa Barbara, California 93106, and Bhupat and Jyoti Mehta School of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Mumbai, India 400076 [D. P.] ABSTRACT prostate cancer, malignant melanoma, and metastatic renal cell carci- noma (12–14). In studies on the antiproliferative actions of coumarin compounds, we In addition, the coumarin anticoagulants, dicoumarol (Dicumarol) -discovered that dicoumarol (a coumarin anticoagulant; 3,3؅-methyl and its synthetic derivative warfarin sodium (Coumadin), have been enebis[4-hydroxycoumarin]) inhibits the first cleavage of Strongylocentro- tus purpuratus (sea urchin) embryos in a concentration-dependent manner shown to decrease metastases in experimental animals (15). Warfarin with 50% inhibition occurring at a concentration of 10 ␮M. Because first sodium, largely replacing dicoumarol therapeutically as an anticoag- cleavage in sea urchin embryos is highly selective for microtubule- ulant, has been used for the treatment of a variety of cancers and targeted agents, we thought that the active compounds might inhibit cell shown to improve tumor response rates and survival in patients with division by interacting with tubulin or microtubules. We found that several types of cancer (16–22). However, despite numerous studies, ␮ dicoumarol binds to bovine brain tubulin with a Kd of 22 M and that 0.1 little information has been acquired on the cellular mechanism of ␮ M dicoumarol strongly stabilizes the growing and shortening dynamics action of coumarin compounds in the treatment of malignancies.
    [Show full text]
  • CHAPTER 1 General Introduction
    CHAPTER 1 General Introduction Chapter 1 1.1 General Introduction Drugs are defined as chemical substances that are used to prevent or cure diseases in humans and animals. Drugs can also act as poisons if taken in excess. For example paracetamol overdose causes coma and death. Apart from the curative effect of drugs, most of them have several unwanted biological effects known as side effects. Aspirin which is commonly used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever and as an anti-inflammatory medication, may also cause gastric irritation and bleeding. Also many drugs, such as antibiotics, when over used develop resistance to the patients, microorganisms and virus which are intended to control by drug. Resistance occurs when a drug is no longer effective in controlling a medical condition.1 Thus, new drugs are constantly required to surmount drug resistance, for the improvement in the treatment of existing diseases, the treatment of newly identified disease, minimise the adverse side effects of existing drugs etc. Drugs are classified in number of different ways depending upon their mode of action such as antithrombotic drugs, analgesic, antianxiety, diuretics, antidepressant and antibiotics etc.2 Antithrombotic drugs are one of the most important classes of drugs which can be shortly defined as ―drugs that reduce the formation of blood clots‖. The blood coagulation, also known as haemostasis is a physiological process in which body prevents blood loss by forming stable clot at the site of injury. Clot formation is a coordinated interplay of two fundamental processes, aggregation of platelets and formation of fibrin.
    [Show full text]
  • Some Aspects of the Pharmacology of Oral Anticoagulants
    Some aspects of the pharmacology of oral anticoagulants The pharmacology of oral anticoagulants ls discussed with particular rejerence to data of value in the management of therapy. The importance of individual variability in response and drug interaction is stressed. Other effects of these agents which may have clinical utility are noted. William W. Coon, M.D., and Park W. Willis 111, M.D., Ann Arbor, Mich. The Departments of Surgery (Section of General Surgery) and Medicine, University of Michigan Medical School In the twenty-five years sinee the isola­ dividual struetural features but by a com­ tion of the hemorrhagie faetor in spoiled bination of several: molecular shape, in­ sweet clever," the gradually inereasing creased aetivity with 6 membered hetero­ utilization of oral antieoagulants for the eyclic rings with a substituent in position prevention and therapy of thromboembolie 8 and with a methoxyl rather than a free disease has made them one of the most hydroxl group. Also important is the dernon­ widely used groups of pharmacologic stration that levorotatory warfarin is seven agents. This review is restrieted to as­ times more aetive than its enantiomer.F" peets of the pharmaeology of these agents As Hunter and Shepherd'" have pointed whieh may be important to their proper out, the failure to obtain a precise cor­ clinieal utilization. relation between strueture and antieoagu­ lant aetivity is "not surprising in view of Relation of structure to function the influence of small struetural changes The oral antieoagulants have been di­ on sueh variables as solubility, rate of ab­ vided into four main groups on the basis sorption, ease of distribution, degree of of ehemieal strueture (Fig.
    [Show full text]